Naarden, The Netherlands – 03 March 2025 – Forbion is pleased to announce the appointment of Regina Salvat, PhD, as Principal in our Boston office. This strategic hire underscores our commitment to strengthening our presence in the United States and enhancing our investment capabilities in the biotech sector.
Regina joins Forbion from Sofinnova Investments, where she was instrumental in driving multiple successful private investments across the biotechnology landscape. She holds a PhD in Protein Engineering from Dartmouth College and a Bachelor’s degree in Biomedical Engineering from Cornell University. Her extensive experience and robust network will be invaluable assets as she collaborates with the Forbion Growth team, focusing on private and crossover investment opportunities.
Regina is no stranger to Forbion, having previously collaborated on successful investments in companies such as Capstan Therapeutics, Aiolos Bio, and Gyroscope Therapeutics. Her proven track record in identifying and nurturing high-impact biotech ventures aligns seamlessly with Forbion’s mission to support innovative companies that transform patient care.
Managing Partner Martien van Osch, co-founder of Forbion, emphasizes the significance of these developments, “The expansion into Boston and the addition of seasoned professionals like Regina reflect Forbion’s dedication to fostering innovation and supporting groundbreaking biotech companies. Our presence in this dynamic biotech hub enables us to better serve our portfolio and identify new investment opportunities that align with our mission to bring transformative therapies to patients.”
The establishment of our Boston office in June 2024 marked a significant milestone in Forbion’s expansion strategy. Located on Clarendon Street, this office serves as a hub for Forbion’s U.S. operations, enabling closer collaboration with portfolio companies and access to a vibrant biotech ecosystem. The Boston team to date includes Managing Partner Martien van Osch, General Partner Josh Brumm and Partner Jonathan McNeill, MD.
Forbion remains committed to building a talented team to drive our mission forward. We are confident that the expertise and leadership of our Boston team will significantly contribute to the growth and success of our portfolio companies and the broader biotech community.
For more information, please contact:
Forbion Communications
Email: laura.asbjornsen@forbion.com
Head of Communications
About Forbion
Forbion is a leading global venture capital firm with deep expertise in Europe and offices in Naarden, The Netherlands, Munich, Germany and Boston, USA. Forbion invests in innovative biotech companies, managing approximately €5 billion across multiple fund strategies that cover all stages of (bio-) pharmaceutical drug development. In addition, Forbion leverages its biotech expertise beyond human health to address ‘planetary health’ challenges through its BioEconomy fund strategy, which invests in companies developing sustainable solutions in food, agriculture, materials, and environmental technologies. Forbion’s team consists of over 30 investment professionals that have built an impressive performance track record since the late nineties with 128 investments across 11 funds. Forbion’s record of sourcing, building and guiding life sciences companies has resulted in many approved breakthrough therapies and valuable exits. Forbion typically selects impactful investments that will positively affect the health and well-being of people and the planet, as well as meet its financial return objectives. The firm is a signatory to the United Nations Principles for Responsible Investment. Forbion operates a joint venture with BGV, the manager of seed and early-stage funds, especially focused on Benelux and Germany.
